LL-37
Antimicrobial peptide. LL-37 is not FDA approved for any use.
Key facts
- Class
- Antimicrobial peptide
- Also called
- cathelicidin
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Unclear
- Not named on the 2026 list
LL-37 guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Injury recovery | Not in our ledger | Not in our ledger | 6 | Human RCT evidence, 4 of 4Archives of dermatological research 2023, PMID 37480520 |
| Skin | Not in our ledger | Not in our ledger | 5 | Human RCT evidence, 4 of 4Archives of dermatological research 2023, PMID 37480520 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
LL-37 is the body's own cathelicidin; the trials test it as a topical wound drug
An ex vivo study found no apparent cleavage of LL-37 in venous ulcer wound fluid for up to 24 h at 37°C, even with resident P. aeruginosa present.[17]
In mice, an intravenous bolus of an LL-37-based radiotracer was rapidly cleared from the blood, largely by the liver; this is animal data about injection, not topical use.[18]
Three randomized topical trials, with mixed results
In a randomised venous leg ulcer trial, wound area improved from pretreatment values at 0.5 and 1.6 mg/mL (p < 0.001 and p = 0.011), while 3.2 mg/mL showed no difference in healing from placebo.[19]
The phase 2b trial found no significant healing improvement in the full study population. A post hoc subgroup with large target wounds did improve.[20]
A randomized trial of an LL-37 cream in diabetic foot ulcers with mild infection found it enhanced the healing rate, but did not lower levels of IL-1α or TNF-α.[5]
Regulatory path
Drugs@FDA lists no LL-37 product.[3]
In the April version of FDA's bulks-list notice, Cathelicidin LL-37 was removed from category 2 because the nomination was withdrawn. FDA said it intended to consult its advisory committee before the end of February 2027.[4]
Common questions
Is LL-37 FDA approved?
No. LL-37 is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026.
What is LL-37?
An endogenous cathelicidin peptide, strongly expressed at the wound edge early in acute wound healing and only weakly in chronic wounds.[17]
What does LL-37 do?
In a phase 2b venous leg ulcer trial, the full study population showed no significant healing improvement over placebo.[20]
Is there an LL-37 nasal spray?
The human trials cited here applied LL-37 topically to ulcers, and no nasal-spray study was found.[19]
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ll-37" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 4US compounding: LL-37 was removed from FDA's 503A category 2 after the nominator withdrew; FDA announced a PCAC consultation before the end of February 2027.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 5Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial.Archives of dermatological research · 2023PMID 37480520Accessed 2 Oct 2026
- 6PubMed search: "LL-37"[tiab] OR LL37[tiab] (3020 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR patients[tiab]) (730 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (ulcer*[tiab] OR wound[tiab]) (261 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (venous[tiab] AND ulcer*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (healed[tiab] OR healing[tiab]) AND (randomized[tiab] OR placebo[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR stability[tiab]) (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (infection[tiab] OR antimicrobial[tiab] OR biofilm[tiab]) AND (mice[tiab] OR rat[tiab] OR murine[tiab]) (386 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 14PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (trial[tiab] OR patients[tiab] OR topical[tiab] OR clinical[tiab]) (87 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 15PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (topical[tiab] OR cream[tiab] OR ulcer*[tiab] OR "phase"[tiab] OR volunteers[tiab]) AND (adverse[tiab] OR safety[tiab] OR tolerab*[tiab] OR irritation[tiab]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 16PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (melanoma[tiab] OR intratumoral[tiab] OR intra-tumoral[tiab]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17Stability of the cathelicidin peptide LL-37 in a non-healing wound environment.Acta dermato-venereologica · 2011PMID 21547341Accessed 2 Oct 2026
- 18Biodistribution of the cationic host defense peptide LL-37 using SPECT/CT.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024PMID 38972467Accessed 2 Oct 2026
- 19Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2014PMID 25041740Accessed 2 Oct 2026
- 20Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2021PMID 34687253Accessed 2 Oct 2026
Found an error? Report a correction.